1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea is a **chemical compound**, and its importance lies in its potential **pharmacological activity**.
Here's a breakdown of its structure and potential uses:
**Structure:**
* **1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea** is a complex molecule with several distinct parts:
* **Phenyl rings:** Two benzene rings are present, one with a chlorine substituent (3-chlorophenyl) and the other with a substituted morpholine group.
* **Urea linkage:** The molecule is connected by a urea linkage, a common feature in many pharmaceutical compounds.
* **Morpholine group:** A morpholine ring (a heterocyclic ring containing oxygen and nitrogen) is attached to the second phenyl ring via an oxo (carbonyl) group.
**Potential Uses:**
This specific compound might have potential applications in the development of **drugs** due to its structural features. However, we need more information to understand its specific research significance:
* **Biological Target:** Knowing the **specific biological target** of the compound is crucial. Does it interact with receptors, enzymes, or other proteins involved in a particular biological pathway?
* **Pharmacological Activity:** What kind of **biological activity** does the compound exhibit? For example, does it demonstrate anti-inflammatory, antimicrobial, or analgesic properties?
* **Research Studies:** Has this compound been investigated in any **preliminary research studies**? Were its activity and safety evaluated in cell cultures or animal models?
**Importance in Research:**
The importance of 1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea in research would depend on the answers to the questions above.
* **If this compound shows promising biological activity**, it might become a lead compound for drug development, leading to new medications for a specific disease.
* **Even if it does not lead to a successful drug**, it could provide valuable insights into the structure-activity relationships of this chemical class, helping researchers design even more effective compounds in the future.
**To understand its importance, you need to know the specific research context.**
Let me know if you have more information about the compound, such as the research group studying it or its proposed use, and I can give you a more detailed answer.
ID Source | ID |
---|---|
PubMed CID | 650428 |
CHEMBL ID | 1530583 |
CHEBI ID | 104991 |
Synonym |
---|
CBMICRO_005435 |
HMS2579L23 |
BIM-0005332.P001 |
OPREA1_329376 |
OPREA1_269937 |
MLS000114212 |
smr000011048 |
1-(3-chloro-phenyl)-3-[4-(morpholine-4-carbonyl)-phenyl]-urea |
MLS000070447 , |
CHEBI:104991 |
AKOS001624051 |
1-(3-chlorophenyl)-3-[4-(morpholine-4-carbonyl)phenyl]urea |
smsf0013983 |
CB07514 |
1-(3-chlorophenyl)-3-(4-morpholin-4-ylcarbonylphenyl)urea |
cid_650428 |
bdbm79638 |
1-(3-chlorophenyl)-3-[4-[4-morpholinyl(oxo)methyl]phenyl]urea |
CHEMBL1530583 |
Q27182661 |
SR-01000451287-1 |
sr-01000451287 |
389084-13-3 |
n-(3-chlorophenyl)-n'-[4-(4-morpholinylcarbonyl)phenyl]urea |
DTXSID101187327 |
Class | Description |
---|---|
ureas | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.0316 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.4752 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
BRCA1 | Homo sapiens (human) | Potency | 11.2202 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
TDP1 protein | Homo sapiens (human) | Potency | 15.6758 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.1189 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
Smad3 | Homo sapiens (human) | Potency | 25.1189 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
P53 | Homo sapiens (human) | Potency | 6.3096 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.5481 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 14.1254 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 11.2202 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
cardiac alpha tropomyosin | Sus scrofa (pig) | EC50 (µMol) | 71.4850 | 1.8300 | 2.3740 | 2.9180 | AID504698 |
troponin I, cardiac muscle | Homo sapiens (human) | EC50 (µMol) | 71.4850 | 1.8300 | 2.3740 | 2.9180 | AID504698 |
troponin T, cardiac muscle isoform 3 | Homo sapiens (human) | EC50 (µMol) | 71.4850 | 1.8300 | 2.3740 | 2.9180 | AID504698 |
troponin C, slow skeletal and cardiac muscles | Homo sapiens (human) | EC50 (µMol) | 71.4850 | 1.8300 | 2.3740 | 2.9180 | AID504698 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |